Autres langues Tarsus Pharmaceuticals, Inc.

Actions

TARS

US87650L1035

Produits pharmaceutiques

Marché Fermé - Nasdaq 22:00:00 02/10/2026			Varia. 5j.	Varia. 1 janv.
73,00 ^USD	-3,26%		-3,55%	-10,85%

17/09	Un administrateur de Tarsus Pharmaceuticals cède des actions pour une valeur de 979 744 dollars, selon un récent document de la SEC	MT
09/09	Tarsus Pharmaceuticals : un dirigeant cède des actions pour un montant de 387 940 dollars, selon un récent document de la SEC	MT

Autres langues

29/09	Tarsus Plans to Present 11 Abstracts Highlighting New Insights in Demodex Blepharitis, Ocular Rosacea and the Real-World Impact of XDEMVY at the American Academy of Optometry 2026 Annual Meeting
17/09	Tarsus Pharmaceuticals Insider Sold Shares Worth $979,744, According to a Recent SEC Filing
09/09	Tarsus Pharmaceuticals Insider Sold Shares Worth $387,940, According to a Recent SEC Filing
09/09	Tarsus Pharmaceuticals Insider Sold Shares Worth $1,220,885, According to a Recent SEC Filing
04/09	Tarsus Pharmaceuticals Shares Rise After Closing Alkeus Pharmaceuticals Acquisition
04/09	Tarsus Pharmaceuticals Closes Acquisition of Alkeus Pharmaceuticals
04/09	Tarsus Pharmaceuticals Completes Acquisition of Alkeus Pharmaceuticals, Expanding Leadership in Eye Care
04/09	Tarsus Pharmaceuticals, Inc. completed the acquisition of Alkeus Pharmaceuticals, Inc.
01/09	Tarsus to Participate in Upcoming Investor Conferences
06/08	Tarsus Pharmaceuticals, Inc. entered into a definitive agreement to acquire Alkeus Pharmaceuticals, Inc. for approximately $800 million.
06/08	Tarsus Pharmaceuticals, Inc. Increased Net Sales Guidance for Full Year 2026
06/08	Tarsus Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
06/08	Tarsus to expand eye disease pipeline with up to $800 million Alkeus acquisition
06/08	Earnings Flash (TARS) Tarsus Pharmaceuticals, Inc. Reports Q2 Revenue $173.9M, vs. FactSet Est of $169.7M
06/08	Tarsus Pharmaceuticals Announces Oversubscribed $125.0 Million Private Placement Equity Financing
06/08	Tarsus Pharmaceuticals to Acquire Alkeus Pharmaceuticals and Advance Eye Care Leadership Position
06/08	Tarsus Reports Second Quarter 2026 Financial Results, Advances Next Phase of Growth
06/08	Deals of the day-Mergers and acquisitions
06/08	Tarsus to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026
15/07	RxSight Names Aziz Mottiwala as CEO
13/07	Tarsus Pharmaceuticals, Inc. Announces Management Changes, Effective July 13, 2026
13/07	Tarsus Pharmaceuticals Appoints Neera Clase as Interim Chief Commercial Officer
13/07	Tarsus Pharmaceuticals Announces Executive Leadership Transition as Company Advances Next Phase of Growth
08/07	Tarsus Pharmaceuticals Buys iRenix Medical
08/07	Tarsus Advances Eye Care Leadership Strategy with Acquisition of iRenix Medical and Late-Stage Asset IRX-101